Research programme: IL1RAP-targeting antibody therapeutics - Cantargia

Drug Profile

Research programme: IL1RAP-targeting antibody therapeutics - Cantargia

Alternative Names: CAN-03; CAN01; CAN02; CAN05; CAN07; CAN08; CAN09; CANxx

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lund University
  • Developer Cantargia
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 36 receptor antagonists; Interleukin-1 receptor accessory protein inhibitors; Interleukin-33-inhibitors; Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic myeloid leukaemia; Solid tumours
  • Research Autoimmune disorders; Cancer; Inflammation

Most Recent Events

  • 29 Jun 2018 Cantargia has patents pending for CAN 01 and CAN 03 in Australia, Brazil, Canada, China, Europe, India, Japan, Mexico, South Korea, USA (Cantargia website, June 2018).
  • 29 Jun 2018 Early research in Cancer in Sweden (Parenteral) before June 2018 (Cantargia website, June 2018)
  • 26 Jun 2018 Cantargia has patent protection for IL1RAP-targeting antibody based therapies for the treatment of haematological cancers and solid tumours in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top